


Claims

1. Use of a compound according to formula (I)



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein

A is a 5-8 membered heterocyclic or carbocyclic group, wherein said carbocyclic group may be fused with aryl, heteroaryl, cycloalkyl or heterocycloalkyl;

X is S, O or NH;

Y<sup>1</sup> and Y<sup>2</sup> are independently S, O or -NH;

Z is S or O;


R<sup>1</sup> is H, CN, carboxy, acyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, halogen, hydroxy, acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, ammonium, sulfonyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyloxy, sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, sulfonylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylamino or carbamate;

$R^2$  is selected from the group comprising or consisting of H, halogen, acyl, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylaminoaryl, aryl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl or heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl-aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, carboxy, cyano, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, nitro, acylamino, ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl carbamate, sulfonylamino, sulfanyl, or sulfonyl;

n is 0, 1 or 2;

for the preparation of a medicament for the prophylaxis and/or treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries;


with the proviso that the following compounds are excluded :



wherein  $R^1$  is a lower alkyl or aralkyl and  $R^2$  is H or a halogen.

2. Use of a compound according to claim 1, wherein said diseases are selected in the group including multiple sclerosis, psoriasis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, lung inflammation, thrombosis or brain infection/inflammation such as meningitis or encephalitis.

3. Use of a compound according to claim 1 wherein said diseases are selected in the group including Alzheimer's disease, Huntington's disease, CNS trauma, stroke or ischemic conditions.
4. Use of a compound according to claim 1, wherein said diseases are selected in the group including atherosclerosis, heart hypertrophy, cardiac myocyte dysfunction, elevated blood pressure or vasoconstriction.
5. Use of a compound according to claim 1, wherein said diseases are selected in the group including chronic obstructive pulmonary disease, anaphylactic shock fibrosis, psoriasis, allergic diseases, asthma, stroke or ischemic conditions, ischemia-reperfusion, platelets aggregation/activation, skeletal muscle atrophy/hypertrophy, leukocyte recruitment in cancer tissue, pancreatitis, multiorgane failure, angiogenesis, invasion metastasis, in particular melanoma, Karposi's sarcoma, acute and chronic bacterial and viral infections, sepsis, transplantation graft rejection, glomerulo sclerosis, glomerulo nephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung or in general lung airways inflammation.
6. Use according to any of the precedent claims, wherein  $Y^1$  and  $Y^2$  are both oxygen.
7. Use according to any of the precedent claims, wherein n is 1 or 2 and  $R^1$  and  $R^2$  are both H.
8. Use of compounds according to any of the preceding claims, wherein X is S,  $Y^1$  and  $Y^2$  are both O,  $R^1$  and  $R^2$  are as above-defined and n is 0.
9. Use according to any of the precedent claims, whereby the thiazolidinone-vinyl fused-benzene derivative has the formula (Ia)



wherein  $Y^1$ ,  $R^1$ ,  $R^2$ ,  $Z$  and  $n$  are as above defined;


$V$  and  $W$  are each independently from each other  $O$ ,  $S$  or  $-NR^3$  wherein  $R^3$  is  $H$  or  $C_1$ - $C_6$  alkyl;

5  $G$  is a  $C_1$ - $C_5$  alkylene or a  $C_1$ - $C_5$  alkenylene group;

$o$  and  $m$  are each independently from each other 0 or 1;

$q$  is an integer from 0 to 4.


10. Use according to claim 9, whereby the thiazolidinone-vinyl fused-benzene derivative has the formula (Ib)



10


wherein  $Y^1$ ,  $R^1$ ,  $R^2$ ,  $V$ ,  $Z$ ,  $W$ ,  $m$ ,  $n$ ,  $o$ ,  $q$  are as above defined and  $p$  is an integer from 1 to 4.

11. Use according to any of claims 9 or 10, whereby the thiazolidinone-vinyl fused-benzene derivative has the formula (Ic)



wherein W as well as R<sup>1</sup> and Y<sup>1</sup> are as above defined.

12. Use according to any of claims 9 or 10, whereby the thiazolidinone-vinyl fused-benzene derivative has the formula (Id) :




5

wherein R<sup>1</sup>, R<sup>2</sup>, Z and n are as above defined; o is 0 or 1;

p is an integer from 1 to 4 and q is an integer from 0 to 4.

13. Use of compounds according to any of claims 9, 10 or 12 wherein Z is O, m is 0, n is 1, p is 1 or 2, q is 1, R<sup>1</sup> and R<sup>2</sup> are each as above defined.
- 10 14. Use of compounds according to any of claims 9, 10 or 12 wherein m is 1, n is 0, p is 1 or 2, q is 0, R<sup>1</sup> and R<sup>2</sup> are each as above defined.
15. Use according to any of claims 9, 10 and 12 to 14 wherein m is 0, n is 1, p is 1 or 2, q is 0, R<sup>1</sup> and R<sup>2</sup> are each as defined in claim 1.
16. Use according to any of claims 9, 10 and 12 to 14 wherein R<sup>1</sup> is halogen or hydrogen.

17. Use according to any of claims 1 to 16 for the modulation, in particular for the inhibition, of the PI3 kinase activity.
18. Use according to claim 17, wherein said PI3 kinase is a PI3 kinase  $\gamma$ .
19. A thiazolidinone-vinyl fused-benzene derivative according to formula (II-a)




5

A is selected from the group consisting of dioxol, dioxin, dihydrofuran, (dihydro) furanyl, (dihydro)oxazinyl, pyridinyl, isooxazolyl, oxazolyl (dihydro)naphthalenyl, pyrimidinyl, triazolyl, imidazolyl, pyrazinyl, thiazolidinyl, thiadiazolyl, oxadiazolyl;

R<sup>2</sup> is selected from the group comprising or consisting of H, halogen, acyl, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl carbamate, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylaminoaryl, aryl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl or heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl-aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, carboxy, cyano, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, nitro, acylamino, ureido, sulfonylamino, sulfanyl, or sulfonyl.

15

20. A thiazolidinone-vinyl fused-benzene derivative according to formula (II)




as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein :

5  $Z, Y^1, R^1, R^2$  are as above defined,  $n$  is 0 or 1.

21. A thiazolidinone-vinyl fused-benzene derivative according to claim 20, wherein  $Y^1$  is O.

22. A thiazolidinone-vinyl fused-benzene derivative according to any claims 20 or 21, wherein  $R^1$  is selected in the group consisting of  $C_1$ - $C_6$ -alkyl,  $C_1$ - $C_6$ -alkyl aryl, aryl,  $C_3$ - $C_8$ -cycloalkyl or heterocycloalkyl,  $C_1$ - $C_6$ -alkyl aryl,  $C_2$ - $C_6$ -alkenyl-aryl or  $C_2$ - $C_6$ -alkynyl aryl.


23. A thiazolidinone-vinyl fused-benzene derivative according to formula (III)



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof,

wherein  $R^1$  and  $R^2$  is as above defined.

24. A thiazolidinone-vinyl fused-benzene derivative according any of formulae (IV), (V) and (VI)



wherein R<sup>1</sup> is selected from the group consisting of hydrogen, halogen, cyano, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, acyl, alkoxy carbonyl, while R<sup>2</sup> is as above defined.

25. A thiazolidinone-vinyl fused-benzene derivative according to any of claims 19 to 24 selected from the group consisting of :

5-(1,3-benzodioxol-5-ylmethylene)-1,3-thiazolidine-2,4-dione  
 5-(1,3-benzodioxol-5-ylmethylene)-2-thioxo-1,3-thiazolidin-4-one  
 5-(2,3-dihydro-1,4-benzodioxin-6-ylmethylene)-1,3-thiazolidine-2,4-dione  
 5-(2,3-dihydro-1-benzofuran-5-ylmethylene)-1,3-thiazolidine-2,4-dione  
 5-[(7-methoxy-1,3-benzodioxol-5-yl)methylene]-1,3-thiazolidine-2,4-dione  
 5-[(9,10-dioxo-9,10-dihydroanthracen-2-yl)methylene]-1,3-thiazolidine-2,4-dione  
 (5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]-1,3-thiazolidine-2,4-dione  
 (5Z)-5-(1,3-dihydro-2-benzofuran-5-ylmethylene)-1,3-thiazolidine-2,4-dione  
 5-(1-benzofuran-5-ylmethylene)-1,3-thiazolidine-2,4-dione  
 5-[(4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methylene]-1,3-thiazolidine-2,4-dione  
 5-(1,3-benzodioxol-5-ylmethylene)-2-imino-1,3-thiazolidin-4-one  
 5-Quinolin-6-ylmethylene-thiazolidine-2,4-dione



5-Quinolin-6-ylmethylene-2-thioxo-thiazolidin-4-one  
2-Imino-5-quinolin-6-ylmethylene-thiazolidin-4-one  
5-(3-Methyl-benzo[d]isoxazol-5-ylmethylene)-thiazolidine-2,4-dione  
5-(4-Phenyl-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione  
5-(4-Dimethylamino-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione  
5-[(4-aminoquinazolin-6-yl)methylene]-1,3-thiazolidine-2,4-dione  
5-[(4-piperidin-1-ylquinazolin-6-yl)methylene]-1,3-thiazolidine-2,4-dione  
5-[(4-morpholin-4-ylquinazolin-6-yl)methylene]-1,3-thiazolidine-2,4-dione  
5-{[4-(benzylamino)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione  
5-{[4-(diethylamino)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione  
5-({4-[(pyridin-2-ylmethyl)amino]quinazolin-6-yl}methylene)-1,3-thiazolidine-2,4-dione  
5-({4-[(pyridin-3-ylmethyl)amino]quinazolin-6-yl}methylene)-1,3-thiazolidine-2,4-dione  
ethyl 1-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl}piperidine-3-carboxylate  
ethyl 1-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl}piperidine-4-carboxylate  
tert-butyl 1-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl}-L-prolinate  
5-{[4-(4-methylpiperazin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione  
5-{[4-(4-pyrimidin-2-ylpiperazin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione  
5-({4-[4-(4-fluorophenyl)piperidin-1-yl]quinazolin-6-yl}methylene)-1,3-thiazolidine-2,4-dione  
5-{[4-(4-benzylpiperidin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione  
5-({4-[4-(2-phenylethyl)piperidin-1-yl]quinazolin-6-yl}methylene)-1,3-thiazolidine-2,4-dione

5-{{4-(4-methylpiperidin-1-yl)quinazolin-6-yl}methylene}-1,3-thiazolidine-2,4-dione

5-{{4-(4-hydroxypiperidin-1-yl)quinazolin-6-yl}methylene}-1,3-thiazolidine-2,4-dione

1-[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-quinazolin-4-yl]-piperidine-4-carboxylic acid

1-[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-quinazolin-4-yl]-piperidine-3-carboxylic acid

1-[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-quinazolin-4-yl]-pyrrolidine-2-carboxylic acid

5-(4-Methylamino-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione

5-(4-Methoxy-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione

2-Imino-5-(4-methylamino-quinazolin-6-ylmethylene)-thiazolidin-4-one

2-Imino-5-(4-piperidine-quinazolin-6-ylmethylene)-thiazolidin-4-one

2-Imino-5-(4-dimethylamino-quinazolin-6-ylmethylene)-thiazolidin-4-one

5-(2-Methyl-2H-benzotriazol-5-ylmethylene)-thiazolidine-2,4-dione

5-(3-Methyl-3H-benzotriazol-5-ylmethylene)-thiazolidine-2,4-dione

5-(3-Ethyl-3H-benzimidazol-5-ylmethylene)-thiazolidine-2,4-dione

5-{{1-(4-phenylbutyl)-1H-benzimidazol-6-yl}methylene}-1,3-thiazolidine-2,4-dione

5-{{1-(prop-2-yn-1-yl)-1H-benzimidazol-6-yl}methylene}-1,3-thiazolidine-2,4-dione

5-{{1-[2-[4-(trifluoromethyl)phenyl]ethyl]-1H-benzimidazol-6-yl}methylene}-1,3-thiazolidine-2,4-dione

5-{{1-[2-(4-hydroxyphenyl)ethyl]-1H-benzimidazol-6-yl}methylene}-1,3-thiazolidine-2,4-dione

methyl 4-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1H-benzimidazol-1-yl}cyclohexanecarboxylate

5-{{1-[2-(5-methoxy-1H-indol-3-yl)ethyl]-1H-benzimidazol-6-yl}methylene}-1,3-thiazolidine-2,4-dione

5-{{1-[(1-methyl-1H-pyrazol-4-yl)methyl]-1H-benzimidazol-6-yl}methylene}-1,3-thiazolidine-2,4-dione

5-({1-[2-(3,4-dimethoxyphenyl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione  
5-({1-[2-(4-phenoxyphenyl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione  
5-({1-[4-(trifluoromethyl)benzyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione  
4-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1H-benzimidazol-1-yl}cyclohexanecarboxylic acid  
  
5-[(1-isobutyl-1H-benzimidazol-6-yl)methylene]-1,3-thiazolidine-2,4-dione  
5-({1-[2-(1,3-benzodioxol-4-yl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione  
5-({1-[2-(2-phenoxyphenyl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione  
5-{{1-(3,3-diphenylpropyl)-1H-benzimidazol-6-yl}methylene}-1,3-thiazolidine-2,4-dione  
5-{{1-(2-methoxybenzyl)-1H-benzimidazol-6-yl}methylene}-1,3-thiazolidine-2,4-dione  
5-{{1-(3-furylmethyl)-1H-benzimidazol-6-yl}methylene}-1,3-thiazolidine-2,4-dione  
  
5-[(1-propyl-1H-benzimidazol-6-yl)methylene]-1,3-thiazolidine-2,4-dione  
5-Quinoxalin-6-ylmethylene-thiazolidine-2,4-dione  
5-Quinoxalin-6-ylmethylene-2-thioxo-thiazolidin-4-one  
2-Imino-5-quinoxalin-6-ylmethylene-thiazolidin-4-one  
5-Benzothiazol-6-ylmethylene-thiazolidine-2,4-dione  
5-(3-Methyl-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione  
5-(2-Bromo-3-methyl-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione  
5-(3-bromo-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione  
3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-acrylic acid ethyl ester  
  
3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-acrylic acid  
5-[3-(3-Oxo-3-piperidin-1-yl-propenyl)-benzofuran-5-ylmethylene]-thiazolidine-2,4-dione

Methyl 1-((3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}prop-2-enoyl)prolinate

Methyl 1-((3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}prop-2-enoyl)-D-prolinate

(5-{3-[(3-oxo-3-pyrrolidin-1-ylprop-1-en-1-yl)-1-benzofuran-5-yl]methylene)-1,3-thiazolidine-2,4-dione

5-{3-[3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione

Methyl 1-(3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}prop-2-enoyl)-L-prolinate

N-cyclohexyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-methylacrylamide

3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-ethyl-N-(2-hydroxyethyl)acrylamide

N-cyclobutyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}acrylamide

5-{3-[3-azetidin-1-yl-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione

5-{3-[3-(1,3-dihydro-2H-isoindol-2-yl)-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione

5-{3-[3-azepan-1-yl-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione

3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-piperidin-1-ylacrylamide

3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-(pyridin-3-ylmethyl)acrylamide

N-cyclohexyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}acrylamide

5-{3-[3-(4-methylpiperazin-1-yl)-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione

N-cycloheptyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}acrylamide

5-{3-[3-(2,5-dihydro-1H-pyrrol-1-yl)-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione

N-cyclopentyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}acrylamide

- 3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-propionic acid ethyl ester
- 3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-propionic acid
- 5-[3-(3-Oxo-3-piperidin-1-yl-propyl)-benzofuran-5-ylmethylene]-thiazolidine-2,4-dione
- 6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic acid tert-butyl ester
- 5-(3,4-Dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione
- 5-(4-Benzoyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione
- 5-(4-Acetyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione
- 6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzo[1,4]oxazine-4-carboxylic acid tert-butyl ester
- [6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-3-oxo-2,3-dihydro-benzo[1,4]-oxazin-4-yl]-acetic acid methyl ester
- N-Benzyl-2-[6-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl]-acetamide
- 5-(4-Butyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione
- 5-(4-Benzyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione
- 5-(2-Chloro-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione
- 5-(3-Amino-benzo[d]isoxazol-5-ylmethylene)-thiazolidine-2,4-dione
- 5-(3-Phenylethynyl-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione
- 5-Benzo[1,2,5]thiadiazol-5-ylmethylene-thiazolidine-2,4-dione
- 5-Benzo[1,2,5]oxadiazol-5-ylmethylene-thiazolidine-2,4-dione
- 5-(2-Methyl-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione

5-(2-Carboxymethyl-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione

5-(3-Bromo-2-fluoro-2,3-dihydro-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione

5-(2-Fluoro-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione

26. A thiazolidinone-vinyl fused-benzene derivative according to any of claims 19 to 25 for use as a medicament.


27. A pharmaceutical composition containing at least one thiazolidinone-vinyl fused-benzene derivative according to any of claims 19 to 25 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

28. Use of a thiazolidinone-vinyl fused-benzene derivative according to any of claims 19 to 25 for the preparation of a medicament for the prophylaxis and/or treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries.

29. Use of a thiazolidinone-vinyl fused-benzene derivative according to claim 28 wherein said diseases are selected in the group including multiple sclerosis, psoriasis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, lung inflammation, thrombosis or brain infection/inflammation such as meningitis or encephalitis.


30. Use of a thiazolidinone-vinyl fused-benzene derivative according to claim 28 wherein the said diseases are selected in the group including Alzheimer's disease, Huntington's disease, CNS trauma, stroke or ischemic conditions.

31. Use of a thiazolidinone-vinyl fused-benzene derivative according to claim 28 wherein said diseases are selected in the group including atherosclerosis, heart hypertrophy, cardiac myocyte dysfunction, elevated blood pressure or vasoconstriction.
32. Use of a thiazolidinone-vinyl fused-benzene derivative according to claim 28 wherein said diseases are selected in the group including chronic obstructive pulmonary disease, anaphylactic shock fibrosis, psoriasis, allergic diseases, asthma, stroke or ischemic conditions, ischemia-reperfusion, platelets aggregation/activation, skeletal muscle atrophy/hypertrophy, leukocyte recruitment in cancer tissue, angiogenesis, invasion metastasis, in particular melanoma, Karposi's sarcoma, acute and chronic bacterial and viral infections, sepsis, transplantation, graft rejection, pancreatitis, multiorgane failure, glomerulo sclerosis, glomerulo nephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung or in general lung airways inflammation.
33. Use according to any of claims 28 to 32 for the modulation, particularly the inhibition of PI3Kinase activity.
34. Use according to claim 33 wherein said PI3Kinase is a PI3Kinase- $\gamma$ .
35. A method of preparing a thiazolidinone-vinyl fused-benzene derivatives of formula (I) according to claim 20 comprising the following step:



wherein R<sup>1</sup>, R<sup>2</sup>, Y<sup>1</sup>, Z and n are as above defined.

33. A method of preparing a thiazolidinone-vinyl fused-benzene derivatives of formula (III) according to claim 23, comprising the following step:



wherein R<sup>1</sup>, R<sup>2</sup> and Y<sup>1</sup> are as above defined.